However, 3-week post-injection of GCSF into AML (AML + GCSF) and AML + CYT (AML + CYT + GCSF), but not (CYT (CYT + GCSF), there was a significant increase in the tubule diameter and cell layers compared to AML-, (AML + CYT)- and CYT-treated groups, respectively (Figure 2E,F). The gene discussed is CSF3; the disease is acute myeloid leukemia.